Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia

Y Cao, S Qin,S Luo,Z Li,Y Cheng, Y Fan,Y Sun,X Yin, X Yuan,W Li,T Liu, C-H Hsu, X Lin,S-B Kim,T Kojima,J Zhang,S-H Lee, Y Bai,K Muro, T Doi,C Bai, K Gu, H-M Pan, L Bai, J-W Yang,Y Cui,W Lu,J Chen

ESMO Open（2022）

Cited 21|Views18

No score

Abstract

•Second-line pembrolizumab versus chemotherapy was investigated in patients with ESCC enrolled in KEYNOTE-181 in Asia.•Pembrolizumab monotherapy was safe and effective in patients with advanced ESCC enrolled in KEYNOTE-181 in Asia.•PD-L1 CPS ≥1 can be used as a predictive marker of pembrolizumab response in patients with ESCC in Asia.

Translated text

Key words

esophageal squamous cell carcinoma,PD-1,PD-L1 CPS,pembrolizumab

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined